CNS Pharmaceuticals Files 8-K
Ticker: CNSP · Form: 8-K · Filed: 2024-05-16T00:00:00.000Z
Sentiment: neutral
Topics: 8-K, financial-reporting
TL;DR
CNS Pharmaceuticals filed an 8-K on May 16, 2024, for operational and financial updates.
AI Summary
CNS Pharmaceuticals, Inc. filed an 8-K on May 16, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing serves as a public notification of significant corporate events or financial updates for CNS Pharmaceuticals, Inc., allowing investors and the public to stay informed.
Risk Assessment
Risk Level: low — The filing is a standard corporate disclosure and does not inherently present new risks based on the provided text.
Key Players & Entities
- CNS Pharmaceuticals, Inc. (company) — Registrant
- May 16, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- Houston, Texas (location) — Principal executive offices
FAQ
What specific information is being reported in this 8-K filing regarding results of operations and financial condition?
The provided text states the 8-K is for 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail the specific results or conditions.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 16, 2024.
What is the state of incorporation for CNS Pharmaceuticals, Inc.?
CNS Pharmaceuticals, Inc. is incorporated in Nevada.
Where are the principal executive offices of CNS Pharmaceuticals, Inc. located?
The principal executive offices are located in Houston, Texas.
What is the SEC file number for CNS Pharmaceuticals, Inc.?
The SEC file number for CNS Pharmaceuticals, Inc. is 001-39126.
Filing Stats: 450 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-05-16 10:56:04
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share CNSP The NASDAQ Stock Marke
Filing Documents
- cns_8k.htm (8-K) — 27KB
- cns_ex9901.htm (EX-99.1) — 14KB
- image_001.jpg (GRAPHIC) — 5KB
- 0001683168-24-003550.txt ( ) — 223KB
- cnsp-20240516.xsd (EX-101.SCH) — 3KB
- cnsp-20240516_lab.xml (EX-101.LAB) — 33KB
- cnsp-20240516_pre.xml (EX-101.PRE) — 22KB
- cns_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On May 16, 2024, CNS Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2024 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit Description 99.1 Press release dated May 16, 2024 104 Cover page Interactive Data File (embedded within the Inline XBRL document) 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CNS Pharmaceuticals, Inc. By: /s/ Chris Downs Chris Downs Chief Financial Officer Dated: May 16, 2024 3